{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:03:51Z","timestamp":1778630631052,"version":"3.51.4"},"reference-count":64,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Graves\u2019 disease is the most common cause of hyperthyroidism in iodine-replete areas and is ultimately due to antibodies interacting with the TSH receptor on thyroid follicular cells [TSH-receptor antibody (TRAb)]. Antithyroid drugs (ATDs) belonging to the family of thionamides are the first-line treatment in Europe. ATD treatment is commonly continued for 18\u201324 months. Its major limitation is the high rate of relapses after drug withdrawal. Factors particularly bound to subsequent relapses are the large thyroid volume, smoking habit, persistence of TRAb in the circulation at the end of treatment, and the post-partum period. Under these conditions, consideration should be given to a definitive therapy for hyperthyroidism (radioiodine treatment, thyroidectomy), particularly if the patient is at risk of cardiovascular complications that might be exacerbated by persistence or recurrence of hyperthyroidism.<\/jats:p>","DOI":"10.1055\/s-0035-1555759","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T04:59:40Z","timestamp":1437541180000},"page":"767-772","source":"Crossref","is-referenced-by-count":36,"title":["Outcome Prediction of Treatment of Graves\u2019 Hyperthyroidism with Antithyroid Drugs"],"prefix":"10.1055","volume":"47","author":[{"given":"E.","family":"Piantanida","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sassi","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gallo","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Spreafico","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Tanda","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bartalena","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","article-title":"Diagnosis and management of Graves disease: a global overview","volume":"9","author":"L Bartalena","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","article-title":"Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update","volume":"37","author":"L Bartalena","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"R S Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0032-1333224","article-title":"Examination of orbital tissues in murine models of Graves\u2019 disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues","volume":"45","author":"KT M Johnson","year":"2013","journal-title":"Horm Metab Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1055\/s-0033-1343451","article-title":"Current insights into animal models of Graves\u2019 disease and orbitopathy","volume":"45","author":"B Wiesweg","year":"2013","journal-title":"Horm Metab Res"},{"key":"ref6","first-page":"444","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in the XXI century","volume":"36","author":"E Piantanida","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40618-014-0136-z","article-title":"An update on the medical treatment of Graves\u2019 hyperthyroidism","volume":"37","author":"M Marin\u00f2","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12688[Epub ahead of print]","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease","author":"L Bartalena","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"H B Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug therapy","volume":"3","author":"P Vitti","year":"1997","journal-title":"Thyroid"},{"key":"ref11","first-page":"1038","article-title":"Age and gender predict the outcome of treatment for Graves\u2019 hyperthyroidism","volume":"85","author":"A Allahabadia","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2013-1954","article-title":"Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis","volume":"98","author":"V Sundaresh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/thy.2012.0612","article-title":"Antithyroid drug treatment for Graves\u2019 disease in children: a long-term retrospective study at a single institution","volume":"24","author":"H Ohye","year":"2014","journal-title":"Thyroid"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-13-0811","article-title":"Long-term prognosis after medical treatment of Graves\u2019 disease in a northern Swedish population 2000-2010","volume":"170","author":"E Mohlin","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003420.pub4","article-title":"Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism","author":"P Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","article-title":"Clinical Practice: Graves\u2019 disease","volume":"358","author":"G A Brent","year":"2008","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1532-5415.1989.tb07279.x","article-title":"Age-related changes of thyroid function and immunologic abnormalities in patients with hyperthyroidism due to Graves\u2019 disease","volume":"37","author":"T Aizawa","year":"1989","journal-title":"J Am Geriatr Soc"},{"key":"ref18","first-page":"622","article-title":"Factors influencing the outcome of thyrostatic drug therapy in Graves\u2019 disease","volume":"122","author":"B Winsa","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves\u2019 disease","volume":"147","author":"B G Nedrebo","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","article-title":"Predictors of long-term remission in patients with Graves\u2019 disease: a single center experience","volume":"44","author":"P Anagnostis","year":"2013","journal-title":"Endocrine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000342621","article-title":"Genotype and phenotype predictors of relapse of Graves\u2019 disease after antithyroid drug withdrawal","volume":"1","author":"P-W Wang","year":"2012","journal-title":"Eur Thyroid J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","article-title":"Is there a a methimazole dose effect on remission rate in Graves\u2019 disease? Results from a long-term prospective study","volume":"49","author":"G Benker","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1210\/jc.2008-0842","article-title":"Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment","volume":"93","author":"F Kaguelidou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1530\/EJE-10-1155","article-title":"Epidemiology of subtypes of hyperthyroidism in Denmark: a polulation-based study","volume":"164","author":"A Carl\u00e9","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1507\/endocrj.K06-069","article-title":"Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves\u2019 disease: a 120 months prospective study","volume":"54","author":"C Cappelli","year":"2007","journal-title":"Endocrine J"},{"key":"ref26","first-page":"427","article-title":"Independent pretreatment predictors of Graves\u2019 disease outcome","volume":"49","author":"D Dauksenie","year":"2013","journal-title":"Medicina (Kaunas)"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/acta.0.1110039","article-title":"Goitre size and outcome of medical treatment of Graves\u2019 disease","volume":"111","author":"P Laurberg","year":"1986","journal-title":"Acta Endocrinol (Copenh)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1210\/jc.2011-1944","article-title":"Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves\u2019 disease: national long-term cohort study","volume":"97","author":"J L\u00e9ger","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2009.0126","article-title":"Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves\u2019 disease","volume":"20","author":"Y K Choo","year":"2010","journal-title":"Thyroid"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2249.2010.04266.x","article-title":"Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins","volume":"162","author":"S D Lytton","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.autrev.2012.07.003","article-title":"TSH receptor autoantibody immunoassay in patients with Graves\u2019 disease: improvement of diagnostic accuracy over different generation of methods. Systematic review and meta-analysis","volume":"12","author":"R Tozzoli","year":"2012","journal-title":"Autoimmunity Rev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1210\/jc.2013-4026","article-title":"Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves\u2019 disease \u2013 a multicenter study","volume":"99","author":"T Diana","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"P Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/eje.1.02295","article-title":"Remission of Graves\u2019 disease during anti-thyroid drug therapy. Time to reconsider the mechanism?","volume":"155","author":"P Laurberg","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40618-013-0026-9","article-title":"Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves\u2019 disease in Croatian patients","volume":"37","author":"M Stefanic","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"ref36","first-page":"98","article-title":"Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves\u2019 disease","volume":"78","author":"U Feldt-Rassmussen","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2012-4309","article-title":"Clinical utility of TSH receptor antibodies","volume":"98","author":"G Barbesino","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"M L Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"M P Mourits","year":"1997","journal-title":"Clin Endocrinol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1055\/s-0033-1349891","article-title":"A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in Graves\u2019 ophthalmopathy patients with different Clinical Activity Score","volume":"45","author":"E Rebelo Pinto","year":"2013","journal-title":"Horm Metab Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02933.x","article-title":"Patients with severe Graves\u2019 ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission","volume":"67","author":"A K Eckstein","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/165487","article-title":"Association between TSH-receptor autoimmunity, hyperthyroidism, goiter, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves\u2019 disease study","author":"P Laurberg","year":"2014","journal-title":"J Thyroid Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","article-title":"A systematic review of drug therapy for Graves\u2019 hyperthyroidism","volume":"153","author":"P Abraham","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/cen.12478","article-title":"Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves\u2019 disease: a retrospective observational study","volume":"81","author":"B Vaidya","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref45","first-page":"593","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","author":"R S Bahn","year":"2011","journal-title":"Thyroid"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs. continuous treatment with low methimazole dose: a retrospective study","volume":"31","author":"E Mazza","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","article-title":"Outcome of very long-term treatment with antithyroid drugs in Graves\u2019 hyperthyroidism associated with Graves\u2019 orbitopathy","volume":"21","author":"L Elbers","year":"2011","journal-title":"Thyroid"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves\u2019 hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves\u2019 orbitopathy","volume":"21","author":"P Laurberg","year":"2011","journal-title":"Thyroid"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/eje.0.1460153","article-title":"Smoking and thyroid disorders \u2013 a meta-analysis","volume":"146","author":"P Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"W M Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jama.2009.557","article-title":"Thyroid-stimulating hormone-receptor antibody and thyroid hormone concentrations in smokers vs nonsmokers with Graves\u2019 disease treated with carbimazole","volume":"301","author":"M J Nyirenda","year":"2009","journal-title":"JAMA"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1089\/thy.2011.0035","article-title":"Development of thyroid dysfunction and autoantibodies in Graves\u2019 multiplex families: an eight-year follow-up study in Chinese Han pedigrees","volume":"12","author":"X Hou","year":"2011","journal-title":"Thyroid"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1530\/eje.0.1440475","article-title":"Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves\u2019 hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study","volume":"144","author":"D Glinoer","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343979","article-title":"Does smoking increase relapse rates in Graves\u2019 disease?","volume":"25","author":"L E Kimball","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.siny.2006.04.003","article-title":"Immunology of normal pregnancy","volume":"11","author":"K M Aagaard-Tyllery","year":"2006","journal-title":"Semin Fetal Neonatal Med"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/thy.1999.9.675","article-title":"The thyroid immunology of the post-partum period","volume":"9","author":"T F Davies","year":"1999","journal-title":"Thyroid"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/thy.1999.9.705","article-title":"Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease","volume":"9","author":"N Amino","year":"1999","journal-title":"Thyroid"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1210\/jc.2008-0966","article-title":"The effect of pregnancy on subsequent relapse from Graves\u2019 disease after a successful course of antithyroid drug therapy","volume":"93","author":"M Rotondi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1365-2265.2002.01615.x","article-title":"Postpartum recurrence of Graves\u2019 hyperthyroidism can be prevented by the continuation of antithyroid drugs during pregnancy","volume":"57","author":"Y Nagakawa","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/cen.12427","article-title":"Graves\u2019 disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?","volume":"80","author":"AP Weetman","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"M Cossburn","year":"2011","journal-title":"Neurology"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"G H Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.md.0000159082.45703.90","article-title":"Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease","volume":"84","author":"F Chen","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1089\/aid.2011.0309","article-title":"Short communication: CD4 cell count increases during successful treatment of Graves\u2019 disease with methimazole in HIV-affected patients on antiretroviral therapy","volume":"28","author":"A Honda","year":"2012","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0035-1555759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:43:08Z","timestamp":1717990988000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0035-1555759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,9,11]]},"published-print":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0035-1555759","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]}}}